No Data
No Data
Qianyuan Pharmaceutical (300254): Net profit turns losses into profit layout opens up new space for AI pharmaceuticals
Report Summary: The company is based on the pharmaceutical business, and net profit in 2023 turned a loss into a profit. The company is mainly engaged in R&D, production, and sales of pharmaceuticals and health care services and commercial businesses such as medical diagnosis, gene preservation, pregnancy environment testing, etc.
Qianyuan Pharmaceutical (300254.SZ): There is no risk of being ST or delisted
On April 17, Gelonghui | Qianyuan Pharmaceutical (300254.SZ) said on the investor interactive platform that according to relevant laws and regulations, the company is not at risk of being ST or delisted.
Qianyuan Pharmaceutical (300254.SZ): Net profit of 18.2844 million yuan for the first quarter reversed year-on-year losses
On April 12, Ge Longhui Pharmaceutical (300254.SZ) released its report for the first quarter of 2024. Operating income for the reporting period was 188 million yuan, up 3.44% year on year; net profit attributable to shareholders of listed companies was 18.2844 million yuan, which turned a year-on-year loss into a profit; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 15.923,800 yuan; basic earnings per share were 0.0757 yuan.
Qianyuan Pharmaceutical (300254.SZ): In 2023, the company sold more than 23 million yuan of tobacco cessation drug varenicline tartrate tablets
On March 29, Ge Longhui | Qianyuan Pharmaceutical (300254.SZ) was surveyed by a specific target on March 28, 2024, on “What is the sales situation of the company's smoking cessation drug vanicline tablets in 2023 and the expected future sales situation?” The company replied that in 2023, the company's smoking cessation drug varenicline tartrate sold more than 23 million yuan; with the continuous expansion of the company's dual-brand multi-channel sales of smoking cessation drugs, it is expected that the company's smoking cessation drugs will maintain a good growth trend in the future.
Qianyuan Pharmaceutical (300254.SZ): An experimental research project approval for CYRJ2308, a class II psychotropic drug for treating epilepsy has been obtained
Gelonghui March 29丨Qianyuan Pharmaceutical (300254.SZ) was surveyed by specific subjects on March 28, 2024, on “What are the areas of refined narcotics developed by the company?” The company replied that the company has obtained approval for experimental research on CYRJ2308, a class II psychotropic drug to treat epilepsy, and that the company will also apply for research and development of project varieties in the fields of depression and migraine treatment.
Qianyuan Pharmaceutical (300254.SZ): Plans to establish a joint venture with Yibao Technology to focus on cooperation in R&D, industrialization and commercialization of innovative drugs based on AI pharmaceutical technology
Gelonghui, March 18, 丨 Qianyuan Pharmaceutical (300254.SZ) announced that on March 16, 2024, Shanxi Qianyuan Pharmaceutical Group Co., Ltd. and Beijing Yiyao Technology Co., Ltd. (“Yibao Technology”) signed a “Joint Venture Agreement”. In the future, the two sides will focus on cooperation in R&D, industrialization and commercialization of innovative drugs based on AI pharmaceutical technology. The registered capital of the joint venture is planned to be RMB 120 million, of which RMB 36 million has been pledged in monetary form and RMB 3 in non-monetary forms such as equipment and technology.
No Data